MERCK Kommanditgesellschaft auf Aktien

XETRA MRK.DE

MERCK Kommanditgesellschaft auf Aktien Price to Sales Ratio (P/S) on January 14, 2025: 2.72

MERCK Kommanditgesellschaft auf Aktien Price to Sales Ratio (P/S) is 2.72 on January 14, 2025, a -9.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • MERCK Kommanditgesellschaft auf Aktien 52-week high Price to Sales Ratio (P/S) is 3.69 on August 30, 2024, which is 35.33% above the current Price to Sales Ratio (P/S).
  • MERCK Kommanditgesellschaft auf Aktien 52-week low Price to Sales Ratio (P/S) is 2.69 on December 19, 2024, which is -1.21% below the current Price to Sales Ratio (P/S).
  • MERCK Kommanditgesellschaft auf Aktien average Price to Sales Ratio (P/S) for the last 52 weeks is 3.20.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
XETRA: MRK.DE

MERCK Kommanditgesellschaft auf Aktien

CEO Ms. Belen Garijo Lopez M.D.
IPO Date June 26, 1998
Location Germany
Headquarters Frankfurter Strasse 250
Employees 62,176
Sector Health Care
Industries
Description

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Similar companies

DB1.DE

Deutsche Börse AG

USD 235.70

1.85%

FME.DE

Fresenius Medical Care AG & Co. KGaA

USD 44.66

0.37%

BEI.DE

Beiersdorf Aktiengesellschaft

USD 127.49

-1.31%

StockViz Staff

January 15, 2025

Any question? Send us an email